secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053974
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q1 net loss $58.3M; cash $435.7M funds operations into 2027
------------------------------------------------------------------------------

- Cash and marketable securities $435.7M as of Mar 31, 2024, up from $273.2M year-end 2023.
- Net loss $58.3M in Q1 2024 vs $38.6M in Q1 2023; R&D expenses $52.7M (up 46% YoY).
- Enrollment on track in APEX, PEAK (end 2024) and SUMMIT (Q2 2025); topline results expected in 2025.
- Completed oversubscribed private placement yielding $213.4M net proceeds.
- Selected 100 mg once-daily dose for SUMMIT Part 2 based on 51% mean TSS improvement at week 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/0000950170-24-053974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/cogt-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer